{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:32:32Z","timestamp":1791048752049,"version":"4.1.0"},"reference-count":63,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Statins are included in the category of high-frequency prescription drugs, and their use is on an upward trend worldwide. In 2012, the FDA issued a warning about possible cognitive adverse drug reactions (ADRs) related to statins, some of which are listed in the Summary of Product Characteristics, but there are still concerns about their potential risk of psychiatric events. The aim of this research was to investigate spontaneous reports containing psychiatric ADRs associated with statins by analyzing the EudraVigilance (EV) database. From January 2004 to July 2021, a total of 8965 ADRs were reported for the Systems Organ Class (SOC) \u201cpsychiatric disorders\u201d, of which 88.64% were registered for atorvastatin (3659), simvastatin (2326) and rosuvastatin (1962). Out of a total of 7947 individual case safety reports (ICSRs) of the 3 statins mentioned above, in 36.3% (2885) of them, statins were considered the only suspected drug, and in 42% (3338), no other co-administered drugs were mentioned. Moreover, insomnia has been reported in 19.3% (1536) of cases, being the most frequent adverse reaction. A disproportionality analysis of psychiatric ADRs was performed. The Reporting Odds Ratio (ROR) and 95% confidence interval (95% CI) were calculated for simvastatin, atorvastatin and rosuvastatin compared with antiplatelets and antihypertensive drugs. The reporting probability for most ADRs of these statins compared to antiplatelets was higher. The reporting probability for insomnia, nightmares and depression produced by statins compared to antihypertensive drugs was also higher. The results of this analysis augment the existing data about a possible correlation between the administration of statins and the occurrence of psychiatric side effects.<\/jats:p>","DOI":"10.3390\/ph15121536","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T01:42:27Z","timestamp":1670809347000},"page":"1536","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Post-Marketing Surveillance of Statins\u2014A Descriptive Analysis of Psychiatric Adverse Reactions in EudraVigilance"],"prefix":"10.3390","volume":"15","author":[{"given":"Gabriela","family":"Pop","sequence":"first","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-8409","authenticated-orcid":false,"given":"Andreea","family":"Farca\u0219","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Research Center, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1540-641X","authenticated-orcid":false,"given":"Anca","family":"Butuc\u0103","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-8729","authenticated-orcid":false,"given":"Claudiu","family":"Morgovan","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca Maria","family":"Arseniu","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Pumnea","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minodora","family":"Teodoru","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3167-9864","authenticated-orcid":false,"given":"Felicia Gabriela","family":"Gligor","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Liu, Y., Lv, X., Xie, N., Fang, Z., Ren, W., Gong, Y., Jin, Y., and Zhang, J. (2020). Time trends analysis of statin prescription prevalence, therapy initiation, dose intensity, and utilization from the hospital information system of Jinshan Hospital, Shanghai (2012\u20132018). BMC Cardiovasc. Disord., 20.","DOI":"10.1186\/s12872-020-01482-5"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2021.05.016","article-title":"Trends in lipid-modifying agent use in 83 countries","volume":"328","author":"Blais","year":"2021","journal-title":"Atherosclerosis"},{"key":"ref_3","first-page":"1","article-title":"Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003\u20132012","volume":"177","author":"Gu","year":"2014","journal-title":"NCHS Data Brief"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40035-018-0110-3","article-title":"The role of statins in both cognitive impairment and protection against dementia: A tale of two mechanisms","volume":"7","author":"Schultz","year":"2018","journal-title":"Transl. Neurodegener."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1212\/WNL.0000000000004837","article-title":"Statin use and risk of Alzheimer disease: A new view on an old relationship","volume":"90","author":"Yasar","year":"2018","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1592\/phco.29.7.800","article-title":"Statin-associated adverse cognitive effects: Survey results from 171 patients","volume":"3329","author":"Evans","year":"2009","journal-title":"Pharmacotherapy"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40800-015-0024-2","article-title":"Mood, Personality, and Behavior Changes during Treatment with Statins: A Case Series","volume":"3","author":"Cham","year":"2016","journal-title":"Drug Saf.-Case Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.medcli.2017.11.030","article-title":"Statins: Pros and cons","volume":"150","author":"Mammen","year":"2018","journal-title":"Med. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2012.07.007","article-title":"The controversies of statin therapy: Weighing the evidence","volume":"60","author":"Jukema","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1532-5415.2007.01071.x","article-title":"Effects of Statin Use on Muscle Strength, Cognition, and Depressive Symptoms in Older Adults","volume":"55","author":"Agostini","year":"2007","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/qjmed\/hcr158","article-title":"Adverse events associated with individual statin treatments for cardiovascular disease: An indirect comparison meta-analysis","volume":"105","author":"Alberton","year":"2012","journal-title":"QJM Int. J. Med."},{"key":"ref_12","unstructured":"(2022, April 16). FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-Lowering Statin Drugs, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs."},{"key":"ref_13","unstructured":"Crestor (2022, March 11). Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/crestor-5-mg-article-29-referral-annex-i-ii-iii_en.pdf."},{"key":"ref_14","unstructured":"Sortis (2022, March 11). Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/sortis-emea\/h\/29-pad\/1255-article-29-paediatrics-referral-annex-i-ii-iii_en.pdf."},{"key":"ref_15","unstructured":"Zocord (2022, March 11). Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/zocord-article-30-referral-annex-i-ii-iii_en.pdf."},{"key":"ref_16","unstructured":"Lescol (2022, March 11). Summary of Product characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/lescol-article-30-referrals-annex-i-iii_en.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1592\/phco.30.6.625","article-title":"Changes in Memory Function and Neuronal Activation Associated with Atorvastatin Therapy","volume":"30","author":"Parker","year":"2010","journal-title":"Pharmacotherapy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000073981","article-title":"Association between Statin Use and Alzheimer\u2019s Disease","volume":"23","author":"Zamrini","year":"2004","journal-title":"Neuroepidemiology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"20607","DOI":"10.3390\/ijms151120607","article-title":"Molecular Mechanisms Underlying the Effects of Statins in the Central Nervous System","volume":"15","author":"McFarland","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1124\/jpet.105.094136","article-title":"Brain Cholesterol Synthesis in Mice Is Affected by High Dose of Simvastatin but Not of Pravastatin","volume":"316","author":"Thelen","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"687585","DOI":"10.3389\/fcvm.2021.687585","article-title":"Hydrophilic or Lipophilic Statins?","volume":"8","author":"Climent","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jacl.2011.06.007","article-title":"Statins and their influence on brain cholesterol","volume":"5","year":"2011","journal-title":"J. Clin. Lipidol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s40264-017-0552-z","article-title":"Lipophilic Statins and the Risk of Intracranial Hemorrhage Following Ischemic Stroke: A Population-Based Study","volume":"40","author":"Quinn","year":"2017","journal-title":"Drug Saf."},{"key":"ref_24","first-page":"CD003160","article-title":"Statins for the prevention of dementia","volume":"2016","author":"McGuinness","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/clc.22338","article-title":"Statins in the elderly: A patient-focused approach","volume":"38","author":"Wilmot","year":"2015","journal-title":"Clin. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"15280","DOI":"10.1038\/s41598-021-94803-3","article-title":"Association between statin use and Alzheimer\u2019s disease with dose response relationship","volume":"11","author":"Jeong","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fpsyt.2019.00103","article-title":"Statins and Inflammation: New Therapeutic Opportunities in Psychiatry","volume":"10","author":"Kim","year":"2019","journal-title":"Front. Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/bjd.19504","article-title":"The value of case reports in pharmacovigilance","volume":"183","author":"Segovia","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1161\/01.ATV.0000120374.59826.1b","article-title":"Brain Cholesterol: Long Secret Life Behind a Barrier","volume":"24","author":"Meaney","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/0140-6736(92)90609-7","article-title":"Low serum cholesterol and suicide","volume":"339","author":"Engelberg","year":"1992","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/jamainternmed.2015.2092","article-title":"Statin Therapy and Risk of Acute Memory Impairment","volume":"175","author":"Strom","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.sleep.2011.12.006","article-title":"Poor sleep as a potential causal factor in aggression and violence","volume":"13","author":"Kamphuis","year":"2012","journal-title":"Sleep Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4103\/0366-6999.225062","article-title":"Effects of Plasma Lipids and Statins on Cognitive Function","volume":"131","author":"Li","year":"2018","journal-title":"Chin. Med. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1027\/0227-5910\/a000260","article-title":"Lipophilic Statin Use and Suicidal Ideation in a Sample of Adults With Mood Disorders","volume":"35","author":"Davison","year":"2014","journal-title":"Crisis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40264-020-01021-3","article-title":"PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database","volume":"44","author":"Zinzi","year":"2021","journal-title":"Drug Saf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00002018-200730030-00003","article-title":"Psychiatric Adverse Reactions with Statins, Fibrates and Ezetimibe","volume":"30","author":"Tatley","year":"2007","journal-title":"Drug Saf."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2329-6887.1000141","article-title":"Examination of the FDA Warning for Statins and Cognitive Dysfunction","volume":"2","author":"Sahebzamani","year":"2014","journal-title":"J. Pharmacovigil."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2018.06.021","article-title":"Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study","volume":"238","author":"Dave","year":"2018","journal-title":"J. Affect. Disord."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Sienkiewicz, K., Burzy\u0144ska, M., Rydlewska-Liszkowska, I., Sienkiewicz, J., and Gaszy\u0144ska, E. (2021). The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19010413"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40264-014-0163-x","article-title":"Association of Statin Use with Sleep Disturbances: Data Mining of a Spontaneous Reporting Database and a Prescription Database","volume":"37","author":"Takada","year":"2014","journal-title":"Drug Saf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2165\/0002018-200831120-00007","article-title":"Statin-Associated Psychiatric Adverse Events","volume":"31","author":"Tuccori","year":"2008","journal-title":"Drug Saf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S2215-0366(20)30311-4","article-title":"Associations between statin use and suicidality, depression, anxiety, and seizures: A Swedish total-population cohort study","volume":"7","author":"Molero","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4103\/1673-5374.226379","article-title":"Neuroprotective effects of statins against amyloid \u03b2-induced neurotoxicity","volume":"13","author":"Li","year":"2018","journal-title":"Neural Regen. Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Kosowski, M., Smolarczyk-Kosowska, J., Hachu\u0142a, M., Malig\u0142\u00f3wka, M., Basiak, M., Machnik, G., Pudlo, R., and Okopie\u0144, B. (2021). The Effects of Statins on Neurotransmission and Their Neuroprotective Role in Neurological and Psychiatric Disorders. Molecules, 26.","DOI":"10.3390\/molecules26102838"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jad.2013.11.026","article-title":"Statins use and risk of depression: A systematic review and meta-analysis","volume":"160","author":"Parsaik","year":"2014","journal-title":"J. Affect. Disord."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"O\u2019Neil, A., Sanna, L., Redlich, C., Sanderson, K., Jacka, F., Williams, L.J., Pasco, J.A., and Berk, M. (2012). The impact of statins on psychological wellbeing: A systematic review and meta-analysis. BMC Med., 10.","DOI":"10.1186\/1741-7015-10-154"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jad.2019.07.002","article-title":"Do statins have an effect on depressive symptoms? A systematic review and meta-analysis","volume":"257","author":"Yatham","year":"2019","journal-title":"J. Affect. Disord."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11883-020-00861-9","article-title":"The Role of Statins in Current Guidelines","volume":"22","author":"Rached","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/bcpt.12808","article-title":"Analysis of National Pharmacovigilance Data Associated with Statin Use in Korea","volume":"121","author":"Kim","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11886-015-0609-5","article-title":"Dyslipidemia and Cardiovascular Disease in Women","volume":"17","year":"2015","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1210\/jc.2010-2061","article-title":"Sex Differences in Lipid and Lipoprotein Metabolism: It\u2019s Not Just about Sex Hormones","volume":"96","author":"Wang","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"13426","DOI":"10.1038\/s41598-018-31695-w","article-title":"Sex differences in lipid metabolism are affected by presence of the gut microbiota","volume":"8","author":"Baars","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ijcard.2016.04.003","article-title":"Somatic symptoms of anxiety and nonadherence to statin therapy","volume":"214","author":"Korhonen","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Golomb, B.A., Dimsdale, J.E., Koslik, H.J., Evans, M.A., Lu, X., Rossi, S., Mills, P.J., White, H.L., and Criqui, M.H. (2015). Statin Effects on Aggression: Results from the UCSD Statin Study, a Randomized Control Trial. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124451"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Schooling, C.M., Au Yeung, S.L., Freeman, G., and Cowling, B.J. (2013). The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med., 11.","DOI":"10.1186\/1741-7015-11-57"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/jwh.2007.0379","article-title":"Lipid-Lowering Medication Use and Aggression Scores in Women: A Report from the NHLBI-Sponsored WISE Study","volume":"17","author":"Olson","year":"2008","journal-title":"J. Women\u2019s Health"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Tisdale, J.E., and Miller, D.A. (2018). Depression. Drug-Induced Diseases: Prevention, Detection, and Management, American Society of Health-System Pharmacists.","DOI":"10.37573\/9781585285310"},{"key":"ref_58","unstructured":"(2021, July 03). EudraVigilance-European Database of Suspected Adverse Drug Reaction Reports. Available online: https:\/\/www.adrreports.eu\/en\/index.html."},{"key":"ref_59","unstructured":"(2021, September 21). European Medicines Agency Guideline on Good Pharmacovigilance Practices (GVP). Available online: http:\/\/www.jfda.jo\/Download\/JPC\/TheGoodPharmacovigilancePracticev2.pdf."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s40264-018-0647-1","article-title":"EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection","volume":"41","author":"Postigo","year":"2018","journal-title":"Drug Saf."},{"key":"ref_61","unstructured":"(2021, July 10). Data Source. EudraVigilance-European Database of Suspected Adverse Drug Reaction Reports. Available online: https:\/\/www.adrreports.eu\/en\/data_source.html."},{"key":"ref_62","unstructured":"(2022, November 14). Screening for Adverse Reactions in EudraVigilance. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/other\/screening-adverse-reactions-eudravigilance_en.pdf."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00228-014-1658-1","article-title":"Reducing the noise in signal detection of adverse drug reactions by standardizing the background: A pilot study on analyses of proportional reporting ratios-by-therapeutic area","volume":"70","author":"Grundmark","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/12\/1536\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:37:45Z","timestamp":1760146665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/12\/1536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":63,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["ph15121536"],"URL":"https:\/\/doi.org\/10.3390\/ph15121536","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,10]]}}}